{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T03:31:47Z","timestamp":1769571107238,"version":"3.49.0"},"reference-count":105,"publisher":"Spandidos Publications","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int J Mol Med"],"DOI":"10.3892\/ijmm.2024.5468","type":"journal-article","created":{"date-parts":[[2024,12,6]],"date-time":"2024-12-06T09:33:11Z","timestamp":1733477591000},"source":"Crossref","is-referenced-by-count":4,"title":["Clinical updates of B\u2011cell maturation antigen\u2011targeted therapy in multiple myeloma (MM) and relapsed\/refractory MM (Review)"],"prefix":"10.3892","volume":"55","author":[{"given":"Rui","family":"Xing","sequence":"first","affiliation":[{"name":"Department of Hematology, Dongyang Hospital Affiliated to Wenzhou Medical University, Dongyang People's Hospital, Dongyang, Zhejiang 322100, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meidan","family":"Wang","sequence":"additional","affiliation":[{"name":"Faculty of Biology, University of Freiburg, D\u201179104 Freiburg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liqun","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Harbin Medical University Cancer Hospital, Harbin, Heilongjiang 150040, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mingyue","family":"Pan","sequence":"additional","affiliation":[{"name":"Faculty of Law, University of Freiburg, D\u201179098 Freiburg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yixi","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Rehabilitation Medicine, Chongqing University Jiangjin Hospital, Chongqing University, Chongqing 402260, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongwei","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Surgery, Affiliated Nanhua Hospital, University of South China, Hengyang, Hunan 421002, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2249","published-online":{"date-parts":[[2024,12,6]]},"reference":[{"key":"key20241227101106_b1-ijmm-55-02-05468","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3322\/caac.21820","article-title":"Cancer statistics, 2024","volume":"74","author":"Siegel","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"key20241227101106_b2-ijmm-55-02-05468","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1016\/j.ccell.2017.02.002","article-title":"Target expression, generation, preclinical activity, and pharmacokinetics of the BCMA-T cell bispecific antibody em801 for multiple myeloma treatment","volume":"31","author":"Seckinger","year":"2017","journal-title":"Cancer Cell"},{"key":"key20241227101106_b3-ijmm-55-02-05468","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/s41408-022-00645-1","article-title":"Induction therapy prior to autologous stem cell transplantation (ASCT) in newly diagnosed multiple myeloma: An update","volume":"12","author":"Bazarbachi","year":"2022","journal-title":"Blood Cancer J"},{"key":"key20241227101106_b4-ijmm-55-02-05468","doi-asserted-by":"publisher","first-page":"e006235","DOI":"10.1136\/jitc-2022-006235","article-title":"Adding liposomal doxorubicin enhances the abscopal effect induced by radiation\/\u03b1PD1 therapy depending on tumor cell mitochondrial DNA and cGAS\/STING","volume":"11","author":"Wang","year":"2023","journal-title":"J Immunother Cancer"},{"key":"key20241227101106_b5-ijmm-55-02-05468","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1016\/j.bbrc.2020.02.136","article-title":"Organ-specific regulation of CHD1 by acute PTEN and p53 loss in mice","volume":"525","author":"Rahmy","year":"2020","journal-title":"Biochem Biophys Res Commun"},{"issue":"Suppl 1","key":"key20241227101106_b6-ijmm-55-02-05468","doi-asserted-by":"publisher","first-page":"e409","DOI":"10.1016\/j.ijrobp.2024.07.910","article-title":"Adding a PPAR\u03b1 agonist enhances t cell-mediated effects of RT in combination with anti-PD-1","volume":"120","author":"Wang","year":"2024","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"key20241227101106_b7-ijmm-55-02-05468","doi-asserted-by":"publisher","first-page":"1688","DOI":"10.1182\/blood-2016-04-711903","article-title":"T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma","volume":"128","author":"Ali","year":"2016","journal-title":"Blood"},{"key":"key20241227101106_b8-ijmm-55-02-05468","doi-asserted-by":"publisher","first-page":"1454683","DOI":"10.3389\/fmicb.2024.1454683","article-title":"Evaluation of mycotoxins, mycobiota and toxigenic fungi in the traditional medicine Radix Dipsaci","volume":"15","author":"Hu","year":"2024","journal-title":"Front Microbiol"},{"key":"key20241227101106_b9-ijmm-55-02-05468","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1111\/j.1365-2141.2012.09241.x","article-title":"Serum B-cell maturation antigen is elevated in multiple myeloma and correlates with disease status and survival","volume":"158","author":"Sanchez","year":"2012","journal-title":"Br J Haematol"},{"key":"key20241227101106_b10-ijmm-55-02-05468","doi-asserted-by":"publisher","first-page":"1227448","DOI":"10.3389\/fonc.2023.1227448","article-title":"Chemotherapy-induced toxic epidermal necrolysis in a patient with multiple myeloma, a case report and literature review","volume":"13","author":"X","year":"2023","journal-title":"Front Oncol"},{"key":"key20241227101106_b11-ijmm-55-02-05468","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.leukres.2018.07.015","article-title":"Quantification of B-cell maturation antigen, a target for novel chimeric antigen receptor T-cell therapy in Myeloma","volume":"71","author":"Salem","year":"2018","journal-title":"Leuk Res"},{"key":"key20241227101106_b12-ijmm-55-02-05468","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1016\/j.annonc.2020.02.016","article-title":"Electronic address clinicalguidelines@esmo.org: Cancer-related fatigue: ESMO clinical practice guidelines for diagnosis and treatment","volume":"31","author":"Fabi","year":"2020","journal-title":"Ann Oncol"},{"key":"key20241227101106_b13-ijmm-55-02-05468","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1089\/hum.2018.001","article-title":"Effective targeting of multiple B-cell maturation antigen-expressing hematological malignances by anti-B-cell maturation antigen chimeric antigen receptor T cells","volume":"29","author":"Friedman","year":"2018","journal-title":"Hum Gene Ther"},{"key":"key20241227101106_b14-ijmm-55-02-05468","doi-asserted-by":"publisher","first-page":"4088","DOI":"10.3390\/jcm10184088","article-title":"BCMA in multiple myeloma-A promising key to therapy","volume":"10","author":"Kleber","year":"2021","journal-title":"J Clin Med"},{"key":"key20241227101106_b15-ijmm-55-02-05468","doi-asserted-by":"publisher","first-page":"5192","DOI":"10.3390\/ijms21155192","article-title":"B-cell maturation antigen (BCMA) as a target for new drug development in relapsed and\/or refractory multiple myeloma","volume":"21","author":"Abramson","year":"2020","journal-title":"Int J Mol Sci"},{"key":"key20241227101106_b16-ijmm-55-02-05468","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1186\/s13045-020-00962-7","article-title":"BCMA-targeted immunotherapy for multiple myeloma","volume":"13","author":"Yu","year":"2020","journal-title":"J Hematol Oncol"},{"key":"key20241227101106_b17-ijmm-55-02-05468","doi-asserted-by":"publisher","first-page":"3225","DOI":"10.1182\/blood-2016-01-691162","article-title":"APRIL and BCMA promote human multiple myeloma growth and immunosuppression in the bone marrow microenvironment","volume":"127","author":"Tai","year":"2016","journal-title":"Blood"},{"key":"key20241227101106_b18-ijmm-55-02-05468","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1615\/CritRevImmunol.v32.i4.10","article-title":"Regulatory roles of the tumor necrosis factor receptor BCMA","volume":"32","author":"Coquery","year":"2012","journal-title":"Crit Rev Immunol"},{"key":"key20241227101106_b19-ijmm-55-02-05468","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1182\/blood-2003-06-2043","article-title":"Expression of BCMA, TACI, and BAFF-R in multiple myeloma: A mechanism for growth and survival","volume":"103","author":"Novak","year":"2004","journal-title":"Blood"},{"key":"key20241227101106_b20-ijmm-55-02-05468","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1038\/s41375-020-0734-z","article-title":"B-cell maturation antigen (BCMA) in multiple myeloma: Rationale for targeting and current therapeutic approaches","volume":"34","author":"Shah","year":"2020","journal-title":"Leukemia"},{"issue":"Suppl 16","key":"key20241227101106_b21-ijmm-55-02-05468","doi-asserted-by":"publisher","first-page":"S5508","DOI":"10.1200\/JCO.2023.41.16_suppl.5508","article-title":"Luveltamab tazevibulin (STRO-002), an anti-folate receptor alpha (FolR\u03b1) antibody drug conjugate (ADC), safety and efficacy in a broad distribution of FolR\u03b1 expression in patients with recurrent epithelial ovarian cancer (OC): Update of STRO-002-GM1 phase 1 dose expansion cohort","volume":"41","author":"Oaknin","year":"2023","journal-title":"J Clin Oncol"},{"key":"key20241227101106_b22-ijmm-55-02-05468","doi-asserted-by":"publisher","first-page":"e256","DOI":"10.1016\/j.ijrobp.2023.06.1204","article-title":"Comparison of two triple therapy regimens for enhancing the abscopal effect in mice","volume":"117","author":"Rao","year":"2023","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"key20241227101106_b23-ijmm-55-02-05468","doi-asserted-by":"publisher","first-page":"LBA106","DOI":"10.1200\/JCO.2023.41.17_suppl.LBA106","article-title":"First phase 3 results from CARTITUDE-4: Cilta-cel versus standard of care (PVd or DPd) in lenalidomide-refractory multiple myeloma","volume":"41","author":"Dhakal","year":"2023","journal-title":"J Clin Oncol"},{"key":"key20241227101106_b24-ijmm-55-02-05468","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1001\/jamaoncol.2017.4600","article-title":"Autologous transplantation for newly diagnosed multiple myeloma in the era of novel agent induction: A systematic review and meta-analysis","volume":"4","author":"Dhakal","year":"2018","journal-title":"JAMA Oncol"},{"key":"key20241227101106_b25-ijmm-55-02-05468","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1016\/j.bbmt.2018.12.141","article-title":"Revised international staging system is predictive and prognostic for early relapse (<24 months) after autologous transplantation for newly diagnosed multiple myeloma","volume":"25","author":"Gopalakrishnan","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"key20241227101106_b26-ijmm-55-02-05468","doi-asserted-by":"publisher","first-page":"2425064","DOI":"10.1080\/07853890.2024.2425064","article-title":"Identification of copper metabolism-related markers in Parkinson's disease","volume":"56","author":"Lin","year":"2024","journal-title":"Ann Med"},{"key":"key20241227101106_b27-ijmm-55-02-05468","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1097\/COH.0b013e32833ed177","article-title":"What are biomarkers?","volume":"5","author":"Strimbu","year":"2010","journal-title":"Curr Opin HIV AIDS"},{"key":"key20241227101106_b28-ijmm-55-02-05468","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1177\/1535370217750088","article-title":"Biomarker definitions and their applications","volume":"243","author":"Califf","year":"2018","journal-title":"Exp Biol Med (Maywood)"},{"key":"key20241227101106_b29-ijmm-55-02-05468","doi-asserted-by":"publisher","first-page":"5924","DOI":"10.18632\/oncotarget.12641","article-title":"Minimal residual disease after transplantation or lenalidomide-based consolidation in myeloma patients: A prospective analysis","volume":"8","author":"Oliva","year":"2017","journal-title":"Oncotarget"},{"key":"key20241227101106_b30-ijmm-55-02-05468","doi-asserted-by":"publisher","first-page":"260","DOI":"10.5045\/kjh.2012.47.4.260","article-title":"Simplified flow cytometric immunophenotyping panel for multiple myeloma, CD56\/CD19\/CD138(CD38)\/CD45, to differentiate neoplastic myeloma cells from reactive plasma cells","volume":"47","author":"Jeong","year":"2012","journal-title":"Korean J Hematol"},{"key":"key20241227101106_b31-ijmm-55-02-05468","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1038\/modpathol.3880435","article-title":"Syndecan-1 (CD138) immunoreactivity in bone marrow biopsies of multiple myeloma: Shed syndecan-1 accumulates in fibrotic regions","volume":"14","author":"Bayer-Garner","year":"2001","journal-title":"Mod Pathol"},{"key":"key20241227101106_b32-ijmm-55-02-05468","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1182\/blood-2017-06-740944","article-title":"CD38 antibodies in multiple myeloma: Back to the future","volume":"131","author":"Van De Donk","year":"2018","journal-title":"Blood"},{"key":"key20241227101106_b33-ijmm-55-02-05468","doi-asserted-by":"publisher","first-page":"3383","DOI":"10.1158\/1078-0432.CCR-15-2224","article-title":"Soluble B-cell maturation antigen mediates tumor-induced immune deficiency in multiple myeloma","volume":"22","author":"Sanchez","year":"2016","journal-title":"Clin Cancer Res"},{"key":"key20241227101106_b34-ijmm-55-02-05468","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1002\/cyto.b.21265","article-title":"Immunophenotype of normal vs myeloma plasma cells: Toward antibody panel specifications for MRD detection in multiple myeloma","volume":"90","author":"Flores-Montero","year":"2016","journal-title":"Cytometry B Clin Cytom"},{"key":"key20241227101106_b35-ijmm-55-02-05468","doi-asserted-by":"publisher","first-page":"1726","DOI":"10.1056\/NEJMoa1817226","article-title":"Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma","volume":"380","author":"Raje","year":"2019","journal-title":"N Engl J Med"},{"key":"key20241227101106_b36-ijmm-55-02-05468","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.leukres.2019.04.008","article-title":"Serum B-cell maturation antigen (BCMA) reduces binding of anti-BCMA antibody to multiple myeloma cells","volume":"81","author":"Chen","year":"2019","journal-title":"Leuk Res"},{"key":"key20241227101106_b37-ijmm-55-02-05468","doi-asserted-by":"publisher","first-page":"2210","DOI":"10.1172\/JCI126397","article-title":"B cell maturation antigen-specific CAR T cells are clinically active in multiple myeloma","volume":"129","author":"Cohen","year":"2019","journal-title":"J Clin Invest"},{"key":"key20241227101106_b38-ijmm-55-02-05468","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1111\/bjh.14145","article-title":"Evaluation of B cell maturation antigen as a target for antibody drug conjugate mediated cytotoxicity in multiple myeloma","volume":"174","author":"Lee","year":"2016","journal-title":"Br J Haematol"},{"key":"key20241227101106_b39-ijmm-55-02-05468","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1038\/s41408-021-00505-4","article-title":"Serum BCMA levels predict outcomes in MGUS and smoldering myeloma patients","volume":"11","author":"Visram","year":"2021","journal-title":"Blood Cancer J"},{"issue":"Suppl 1","key":"key20241227101106_b40-ijmm-55-02-05468","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1182\/blood-2018-99-119190","article-title":"Baseline and early changes in serum B-cell maturation antigen levels predict progression free survival and response status for multiple myeloma patients in a phase 1 trial evaluating ruxolitinib, lenalidomide and methylprednisolone","volume":"132","author":"Bujarski","year":"2018","journal-title":"Blood"},{"key":"key20241227101106_b41-ijmm-55-02-05468","doi-asserted-by":"publisher","first-page":"785","DOI":"10.3324\/haematol.2016.150896","article-title":"Serum B-cell maturation antigen: A novel biomarker to predict outcomes for multiple myeloma patients","volume":"102","author":"Ghermezi","year":"2017","journal-title":"Haematologica"},{"issue":"Suppl 1","key":"key20241227101106_b42-ijmm-55-02-05468","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1182\/blood-2018-99-113548","article-title":"JCARH125, anti-BCMA CAR T-cell Therapy for relapsed\/refractory multiple myeloma: Initial proof of concept results from a phase 1\/2 multicenter study (EVOLVE)","volume":"132","author":"Mailankody","year":"2018","journal-title":"Blood"},{"key":"key20241227101106_b43-ijmm-55-02-05468","doi-asserted-by":"publisher","first-page":"2863","DOI":"10.1200\/JCO.2015.61.2267","article-title":"Revised international staging system for multiple myeloma: A report from international myeloma working group","volume":"33","author":"Palumbo","year":"2015","journal-title":"J Clin Oncol"},{"key":"key20241227101106_b44-ijmm-55-02-05468","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1093\/annonc\/mdr276","article-title":"The international scoring system (ISS) for multiple myeloma remains a robust prognostic tool independently of patients' renal function","volume":"23","author":"Dimopoulos","year":"2012","journal-title":"Ann Oncol"},{"key":"key20241227101106_b45-ijmm-55-02-05468","doi-asserted-by":"publisher","first-page":"5428","DOI":"10.1158\/1078-0432.CCR-16-0866","article-title":"New developments in diagnosis, prognosis, and assessment of response in multiple myeloma","volume":"22","author":"Landgren","year":"2016","journal-title":"Clin Cancer Res"},{"key":"key20241227101106_b46-ijmm-55-02-05468","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1179\/102453309X385250","article-title":"Fluorescent in situ hybridization studies in multiple myeloma","volume":"14","author":"Yuregir","year":"2009","journal-title":"Hematology"},{"key":"key20241227101106_b47-ijmm-55-02-05468","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.mne.2018.10.006","article-title":"Fluorescence in situ hybridization (FISH): History, limitations and what to expect from micro-scale FISH?","volume":"1","author":"Huber","year":"2018","journal-title":"Micro Nano Eng"},{"key":"key20241227101106_b48-ijmm-55-02-05468","doi-asserted-by":"publisher","first-page":"7333","DOI":"10.1038\/ncomms8333","article-title":"\u03b3-Secretase directly sheds the survival receptor BCMA from plasma cells","volume":"6","author":"Laurent","year":"2015","journal-title":"Nat Commun"},{"key":"key20241227101106_b49-ijmm-55-02-05468","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1002\/art.38950","article-title":"BAFF regulates follicular helper t cells and affects their accumulation and interferon-\u03b3 production in autoimmunity","volume":"67","author":"Coquery","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"key20241227101106_b50-ijmm-55-02-05468","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1038\/s41408-021-00498-0","article-title":"Minimal residual disease assessment by multiparameter flow cytometry in transplant-eligible myeloma in the EMN02\/HOVON 95 MM trial","volume":"11","author":"Oliva","year":"2021","journal-title":"Blood Cancer J"},{"key":"key20241227101106_b51-ijmm-55-02-05468","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1080\/14737159.2018.1448269","article-title":"The clinical significance of B-cell maturation antigen as a therapeutic target and biomarker","volume":"18","author":"Sanchez","year":"2018","journal-title":"Expert Rev Mol Diagn"},{"key":"key20241227101106_b52-ijmm-55-02-05468","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.1158\/1535-7163.MCT-21-0035","article-title":"Belantamab mafodotin (GSK2857916) drives immunogenic cell death and immune-mediated antitumor responses in vivo","volume":"20","author":"Montes De Oca","year":"2021","journal-title":"Mol Cancer Ther"},{"key":"key20241227101106_b53-ijmm-55-02-05468","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1038\/s41408-019-0196-6","article-title":"Antibody-drug conjugate, GSK2857916, in relapsed\/refractory multiple myeloma: an update on safety and efficacy from dose expansion phase I study","volume":"9","author":"Trudel","year":"2019","journal-title":"Blood Cancer J"},{"key":"key20241227101106_b54-ijmm-55-02-05468","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1038\/leu.2017.60","article-title":"Monoclonal antibody therapy in multiple myeloma","volume":"31","author":"Touzeau","year":"2017","journal-title":"Leukemia"},{"key":"key20241227101106_b55-ijmm-55-02-05468","doi-asserted-by":"publisher","first-page":"640","DOI":"10.3390\/curroncol28010063","article-title":"Belantamab mafodotin to treat multiple myeloma: A comprehensive review of disease, drug efficacy and side effects","volume":"28","author":"Lassiter","year":"2021","journal-title":"Curr Oncol"},{"key":"key20241227101106_b56-ijmm-55-02-05468","doi-asserted-by":"publisher","first-page":"1641","DOI":"10.1016\/S1470-2045(18)30576-X","article-title":"Targeting B-cell maturation antigen with GSK2857916 antibody-drug conjugate in relapsed or refractory multiple myeloma (BMA117159): A dose escalation and expansion phase 1 trial","volume":"19","author":"Trudel","year":"2018","journal-title":"Lancet Oncol"},{"key":"key20241227101106_b57-ijmm-55-02-05468","doi-asserted-by":"publisher","first-page":"3128","DOI":"10.1182\/blood-2013-10-535088","article-title":"Novel anti-B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma","volume":"123","author":"Tai","year":"2014","journal-title":"Blood"},{"key":"key20241227101106_b58-ijmm-55-02-05468","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1038\/s41375-020-0834-9","article-title":"Phase 1 study of the anti-BCMA antibody-drug conjugate AMG 224 in patients with relapsed\/refractory multiple myeloma","volume":"35","author":"Lee","year":"2021","journal-title":"Leukemia"},{"issue":"Suppl 1","key":"key20241227101106_b59-ijmm-55-02-05468","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1182\/blood-2021-150866","article-title":"Pharmacodynamics of SEA-BCMA, a nonfucosylated antibody targeting BCMA, in patients with relapsed\/refractory multiple myeloma","volume":"138","author":"Taft","year":"2021","journal-title":"Blood"},{"issue":"Suppl 1","key":"key20241227101106_b60-ijmm-55-02-05468","doi-asserted-by":"publisher","first-page":"S26","DOI":"10.1182\/blood-2020-136375","article-title":"Phase 1, first-in-human study of MEDI2228, a BCMA-targeted ADC in patients with relapsed\/refractory multiple myeloma","volume":"136","author":"Kumar","year":"2020","journal-title":"Blood"},{"key":"key20241227101106_b61-ijmm-55-02-05468","doi-asserted-by":"publisher","first-page":"5376","DOI":"10.1158\/1078-0432.CCR-21-1621","article-title":"BCMA-specific ADC MEDI2228 and daratumumab induce synergistic myeloma cytotoxicity via IFN-driven immune responses and enhanced CD38 expression","volume":"27","author":"Xing","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"Suppl 1","key":"key20241227101106_b62-ijmm-55-02-05468","doi-asserted-by":"publisher","first-page":"S2740","DOI":"10.1182\/blood-2021-146047","article-title":"SEA-BCMA, an investigational nonfucosylated monoclonal antibody: Ongoing results of a phase 1 study in patients with relapsed\/refractory multiple myeloma (SGNBCMA-001)","volume":"138","author":"Hoffman","year":"2021","journal-title":"Blood"},{"issue":"16Suppl","key":"key20241227101106_b63-ijmm-55-02-05468","doi-asserted-by":"publisher","first-page":"S8007","DOI":"10.1200\/JCO.2022.40.16_suppl.8007","article-title":"Teclistamab, a B-cell maturation antigen (BCMA) x CD3 bispecific antibody, in patients with relapsed\/refractory multiple myeloma (RRMM): Updated efficacy and safety results from MajesTEC-1","volume":"40","author":"Nooka","year":"2022","journal-title":"J ClinOncol"},{"key":"key20241227101106_b64-ijmm-55-02-05468","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1038\/icb.2014.93","article-title":"Bispecific T-cell engagers for cancer immunotherapy","volume":"93","author":"Huehls","year":"2015","journal-title":"Immunol Cell Biol"},{"key":"key20241227101106_b65-ijmm-55-02-05468","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1016\/j.ccell.2023.02.008","article-title":"The pre-existing T cell landscape determines the response to bispecific T cell engagers in multiple myeloma patients","volume":"41","author":"Friedrich","year":"2023","journal-title":"Cancer Cell"},{"key":"key20241227101106_b66-ijmm-55-02-05468","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.ymeth.2018.10.026","article-title":"Bispecific T-cell engagers: Towards understanding variables influencing the in vitro potency and tumor selectivity and their modulation to enhance their efficacy and safety","volume":"154","author":"Ellerman","year":"2019","journal-title":"Methods"},{"key":"key20241227101106_b67-ijmm-55-02-05468","doi-asserted-by":"publisher","first-page":"2196","DOI":"10.1182\/bloodadvances.2020003805","article-title":"Preclinical activity and determinants of response of the GPRC5DxCD3 bispecific antibody talquetamab in multiple myeloma","volume":"5","author":"Verkleij","year":"2021","journal-title":"Blood Adv"},{"key":"key20241227101106_b68-ijmm-55-02-05468","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1111\/j.1365-2362.2012.02679.x","article-title":"Overexpression of G protein-coupled receptor 5D in the bone marrow is associated with poor prognosis in patients with multiple myeloma","volume":"42","author":"Atamaniuk","year":"2012","journal-title":"Eur J Clin Invest"},{"issue":"Suppl 1","key":"key20241227101106_b69-ijmm-55-02-05468","doi-asserted-by":"publisher","first-page":"S5567","DOI":"10.1182\/blood-2019-129652","article-title":"Bispecific T-cell engager (BiTE) antibody based immunotherapy for treatment of relapsed refractory multiple myeloma (RRMM): A systematic review of preclinical and clinical trials","volume":"134","author":"Shah","year":"2019","journal-title":"Blood"},{"key":"key20241227101106_b70-ijmm-55-02-05468","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1016\/S0140-6736(21)01338-6","article-title":"Teclistamab, a B-cell maturation antigen x CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): A multicentre, open-label, single-arm, phase 1 study","volume":"398","author":"Usmani","year":"2021","journal-title":"Lancet"},{"issue":"16 Suppl","key":"key20241227101106_b71-ijmm-55-02-05468","doi-asserted-by":"publisher","first-page":"TPS8072","DOI":"10.1200\/JCO.2022.40.16_suppl.TPS8072","article-title":"MajesTEC-3: Randomized, phase 3 study of teclistamab plus daratumumab versus investigator's choice of daratumumab, pomalidomide, and dexamethasone or daratumumab, bortezomib, and dexamethasone in patients with relapsed\/refractory multiple myeloma","volume":"40","author":"Mateos","year":"2022","journal-title":"J Clin Oncol"},{"issue":"Suppl 1","key":"key20241227101106_b72-ijmm-55-02-05468","doi-asserted-by":"publisher","first-page":"S41","DOI":"10.1182\/blood-2020-139192","article-title":"REGN5458, a BCMA x CD3 bispecific monoclonal antibody, induces deep and durable responses in patients with relapsed\/refractory multiple myeloma (RRMM)","volume":"136","author":"Madduri","year":"2020","journal-title":"Blood"},{"issue":"Suppl 16","key":"key20241227101106_b73-ijmm-55-02-05468","doi-asserted-by":"publisher","first-page":"S8006","DOI":"10.1200\/JCO.2023.41.16_suppl.8006","article-title":"LINKER-MM1 study: Linvoseltamab (REGN5458) in patients with relapsed\/refractory multiple myeloma","volume":"41","author":"Lee","year":"2023","journal-title":"J Clin Oncol"},{"issue":"Suppl 1","key":"key20241227101106_b74-ijmm-55-02-05468","doi-asserted-by":"publisher","first-page":"S4444","DOI":"10.1182\/blood-2022-157713","article-title":"Trial in progress: REGN5458, a BCMAxCD3 bispecific antibody, in a phase Ib multi-cohort study of combination regimens for patients with relapsed\/refractory multiple myeloma","volume":"140","author":"Rodr\u00edguez Otero","year":"2022","journal-title":"Blood"},{"issue":"Suppl 1","key":"key20241227101106_b75-ijmm-55-02-05468","doi-asserted-by":"publisher","first-page":"S195","DOI":"10.1016\/j.htct.2021.10.331","article-title":"Efficacy and safety of elranatamab (PF-06863135), A B-cell maturation antigen (BCMA)-CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma","volume":"43","author":"Solh","year":"2021","journal-title":"Hematol Transfus Cell Ther"},{"issue":"Suppl 1","key":"key20241227101106_b76-ijmm-55-02-05468","doi-asserted-by":"publisher","first-page":"S1869","DOI":"10.1182\/blood-2019-121805","article-title":"Safety, clinical activity, pharmacokinetics, and pharmacodynamics from a phase I study of PF-06863135, a B-cell maturation antigen (BCMA)-CD3 bispecific antibody, in patients with relapsed\/refractory multiple myeloma (RRMM)","volume":"134","author":"Raje","year":"2019","journal-title":"Blood"},{"key":"key20241227101106_b77-ijmm-55-02-05468","doi-asserted-by":"publisher","first-page":"2570","DOI":"10.1038\/s41591-023-02589-w","article-title":"Elranatamab in relapsed or refractory multiple myeloma: The MagnetisMM-1 phase 1 trial","volume":"29","author":"Bahlis","year":"2023","journal-title":"Nat Med"},{"key":"key20241227101106_b78-ijmm-55-02-05468","doi-asserted-by":"publisher","first-page":"2259","DOI":"10.1038\/s41591-023-02528-9","article-title":"Elranatamab in relapsed or refractory multiple myeloma: Phase 2 MagnetisMM-3 trial results","volume":"29","author":"Lesokhin","year":"2023","journal-title":"Nat Med"},{"issue":"Suppl","key":"key20241227101106_b79-ijmm-55-02-05468","doi-asserted-by":"publisher","first-page":"e0036307","DOI":"10.1097\/01.HS9.0000970352.00363.07","article-title":"P862: A phase 1 first-in-human monotherapy study of ABBV-383, A BCMA x CD3 bispecific T-CELL\u2013redirecting antibody, in relapsed\/refractory multiple myeloma","volume":"7","author":"Weisel","year":"2023","journal-title":"Hemasphere"},{"key":"key20241227101106_b80-ijmm-55-02-05468","doi-asserted-by":"publisher","first-page":"3576","DOI":"10.1200\/JCO.22.01504","article-title":"A phase I first-in-human study of ABBV-383, a B-cell maturation antigen x CD3 bispecific T-cell redirecting antibody, in patients with relapsed\/refractory multiple myeloma","volume":"40","author":"D'Souza","year":"2022","journal-title":"J Clin Oncol"},{"issue":"Suppl 1","key":"key20241227101106_b81-ijmm-55-02-05468","doi-asserted-by":"publisher","first-page":"S3378","DOI":"10.1182\/blood-2023-182388","article-title":"Updated safety and efficacy results of Abbv-383, a BCMA x CD3 bispecific T-cell redirecting antibody, in a first-in-human phase 1 study in patients with relapsed\/refractory multiple myeloma","volume":"142","author":"Vij","year":"2023","journal-title":"Blood"},{"issue":"Suppl 1","key":"key20241227101106_b82-ijmm-55-02-05468","doi-asserted-by":"publisher","first-page":"S900","DOI":"10.1182\/blood-2021-150757","article-title":"A phase 1 first-in-human study of Tnb-383B, a BCMA x CD3 bispecific T-cell redirecting antibody, in patients with relapsed\/refractory multiple myeloma","volume":"138","author":"Kumar","year":"2021","journal-title":"Blood"},{"issue":"Suppl 1","key":"key20241227101106_b83-ijmm-55-02-05468","doi-asserted-by":"publisher","first-page":"S28","DOI":"10.1182\/blood-2020-134063","article-title":"A phase 1 first in human (FIH) study of AMG 701, an anti-B-cell maturation antigen (BCMA) half-life extended (HLE) BiTE\u00ae (bispecific T-cell engager) molecule, in relapsed\/refractory (RR) multiple myeloma (MM)","volume":"136","author":"Harrison","year":"2020","journal-title":"Blood"},{"key":"key20241227101106_b84-ijmm-55-02-05468","doi-asserted-by":"publisher","first-page":"4180","DOI":"10.1182\/bloodadvances.2020002565","article-title":"AMG 701 induces cytotoxicity of multiple myeloma cells and depletes plasma cells in cynomolgus monkeys","volume":"4","author":"Goldstein","year":"2020","journal-title":"Blood Adv"},{"issue":"Suppl 1","key":"key20241227101106_b85-ijmm-55-02-05468","doi-asserted-by":"publisher","first-page":"S143","DOI":"10.1182\/blood-2019-122895","article-title":"First clinical study of the B-cell maturation antigen (BCMA) 2+1 T cell engager (TCE) CC-93269 in patients (Pts) with relapsed\/refractory multiple myeloma (RRMM): Interim results of a phase 1 multicenter trial","volume":"134","author":"Costa","year":"2019","journal-title":"Blood"},{"issue":"Suppl 1","key":"key20241227101106_b86-ijmm-55-02-05468","doi-asserted-by":"publisher","first-page":"e1220745","DOI":"10.1097\/01.HS9.0000970436.12207.45","article-title":"P883: Alnuctamab (ALNUC; BMS-986349; CC-93269), A BCMA x CD3 T-cell engager, in patients (PTS) with relapsed\/refractory multiple myeloma (RRMM): Latest results from a phase 1 first-in-human clinical study","volume":"7","author":"Wong","year":"2023","journal-title":"Hemasphere"},{"issue":"Suppl 1","key":"key20241227101106_b87-ijmm-55-02-05468","doi-asserted-by":"publisher","first-page":"S400","DOI":"10.1182\/blood-2022-159009","article-title":"Alnuctamab (ALNUC; BMS-986349; CC-93269), a B-cell maturation antigen (BCMA) x CD3 T-cell engager (TCE), in patients (pts) with relapsed\/refractory multiple myeloma (RRMM): Results from a phase 1 first-in-human clinical study","volume":"140","author":"Wong","year":"2022","journal-title":"Blood"},{"key":"key20241227101106_b88-ijmm-55-02-05468","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1186\/s13045-020-01001-1","article-title":"Safety and clinical efficacy of BCMA CAR-T-cell therapy in multiple myeloma","volume":"13","author":"Roex","year":"2020","journal-title":"J Hematol Oncol"},{"key":"key20241227101106_b89-ijmm-55-02-05468","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1186\/s11658-023-00505-1","article-title":"Exosomal miR-155-5p drives widespread macrophage M1 polarization in hypervirulent Klebsiella pneumoniae-induced acute lung injury via the MSK1\/p38-MAPK axis","volume":"28","author":"Xu","year":"2023","journal-title":"Cell Mol Biol Lett"},{"issue":"Suppl 16","key":"key20241227101106_b90-ijmm-55-02-05468","doi-asserted-by":"publisher","first-page":"S8004","DOI":"10.1200\/JCO.2023.41.16_suppl.8004","article-title":"Updated phase I study results of PHE885, a T-charge manufactured BCMA-directed CAR-T cell therapy, for patients (pts) with r\/r multiple myeloma (RRMM)","volume":"41","author":"Sperling","year":"2023","journal-title":"J Clin Oncol"},{"key":"key20241227101106_b91-ijmm-55-02-05468","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1038\/s41408-021-00469-5","article-title":"CAR T-cell therapy in multiple myeloma: More room for improvement","volume":"11","author":"Teoh","year":"2021","journal-title":"Blood Cancer J"},{"key":"key20241227101106_b92-ijmm-55-02-05468","doi-asserted-by":"publisher","first-page":"e003847","DOI":"10.1136\/jitc-2021-003847","article-title":"Single-center experience using anakinra for steroid-refractory immune effector cell-associated neurotoxicity syndrome (ICANS)","volume":"10","author":"Wehrli","year":"2022","journal-title":"J Immunother Cancer"},{"key":"key20241227101106_b93-ijmm-55-02-05468","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1038\/s41467-019-14119-9","article-title":"Anti-BCMA chimeric antigen receptors with fully human heavy-chain-only antigen recognition domains","volume":"11","author":"Lam","year":"2020","journal-title":"Nat Commun"},{"key":"key20241227101106_b94-ijmm-55-02-05468","doi-asserted-by":"publisher","first-page":"e358","DOI":"10.1016\/S2665-9913(20)30096-5","article-title":"Silencing the cytokine storm: The use of intravenous anakinra in haemophagocytic lymphohistiocytosis or macrophage activation syndrome","volume":"2","author":"Mehta","year":"2020","journal-title":"Lancet Rheumatol"},{"key":"key20241227101106_b95-ijmm-55-02-05468","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1007\/s12185-023-03538-6","article-title":"Phase 2 results of idecabtagene vicleucel (ide-cel, bb2121) in Japanese patients with relapsed and refractory multiple myeloma","volume":"117","author":"Minakata","year":"2023","journal-title":"Int J Hematol"},{"key":"key20241227101106_b96-ijmm-55-02-05468","doi-asserted-by":"publisher","first-page":"2890","DOI":"10.1182\/blood.2020008936","article-title":"A phase 1 study of a novel fully human BCMA-targeting CAR (CT103A) in patients with relapsed\/refractory multiple myeloma","volume":"137","author":"Wang","year":"2021","journal-title":"Blood"},{"issue":"Suppl 1","key":"key20241227101106_b97-ijmm-55-02-05468","doi-asserted-by":"publisher","first-page":"S4854","DOI":"10.1182\/blood-2023-181394","article-title":"Long-term follow-up of fully human BCMA-targeting CAR (CT103A) in patients with relapsed\/refractory multiple myeloma","volume":"142","author":"Li","year":"2023","journal-title":"Blood"},{"issue":"Suppl 1","key":"key20241227101106_b98-ijmm-55-02-05468","doi-asserted-by":"publisher","first-page":"e84060bf","DOI":"10.1097\/01.HS9.0000970380.84060.bf","article-title":"P869: Updated results of a phase I, open-label study of bcma\/cd19 dual-targeting fastcar-T GC012F for patients with relapsed\/refractory multiple myeloma (RRMM)","volume":"7","author":"Du","year":"2023","journal-title":"Hemasphere"},{"issue":"Suppl 16","key":"key20241227101106_b99-ijmm-55-02-05468","doi-asserted-by":"publisher","first-page":"S2049","DOI":"10.1200\/JCO.2022.40.16_suppl.2049","article-title":"Prognostic value of hPG80 (circulating progastrin) in IDH-wild type glioblastoma treated with radio-chemotherapy","volume":"40","author":"Doucet","year":"2022","journal-title":"J Clin Oncol"},{"issue":"Suppl 1","key":"key20241227101106_b100-ijmm-55-02-05468","doi-asserted-by":"publisher","first-page":"S959","DOI":"10.1182\/blood-2018-99-119717","article-title":"Clinical responses and pharmacokinetics of MCARH171, a human-derived bcma targeted CAR T cell therapy in relapsed\/refractory multiple myeloma: Final results of a phase I clinical trial","volume":"132","author":"Mailankody","year":"2018","journal-title":"Blood"},{"key":"key20241227101106_b101-ijmm-55-02-05468","doi-asserted-by":"publisher","first-page":"e004400","DOI":"10.1136\/jitc-2021-004400","article-title":"PD-L1 blockade restores CAR T cell activity through IFN-\u03b3-regulation of CD163+ M2 macrophages","volume":"10","author":"Yamaguchi","year":"2022","journal-title":"J Immunother Cancer"},{"key":"key20241227101106_b102-ijmm-55-02-05468","doi-asserted-by":"publisher","first-page":"3562","DOI":"10.1182\/bloodadvances.2023012416","article-title":"CD4+ CAR T-cell exhaustion associated with early relapse of multiple myeloma after BCMA CAR T-cell therapy","volume":"8","author":"Ledergor","year":"2024","journal-title":"Blood Adv"},{"key":"key20241227101106_b103-ijmm-55-02-05468","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1002\/JLB.3MR0820-685R","article-title":"Regulatory functions of NK cells during infections and cancer","volume":"109","author":"Zwirner","year":"2021","journal-title":"J Leukoc Biol"},{"key":"key20241227101106_b104-ijmm-55-02-05468","first-page":"3453","article-title":"Interferon stimulated gene 15 constitutively produced by melanoma cells induces e-cadherin expression on human dendritic cells","volume":"62","author":"Padovan","year":"2002","journal-title":"Cancer Res"},{"key":"key20241227101106_b105-ijmm-55-02-05468","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/s40164-023-00402-5","article-title":"Identification of potential resistance mechanisms and therapeutic targets for the relapse of BCMA CAR-T therapy in relapsed\/refractory multiple myeloma through single-cell sequencing","volume":"12","author":"Li","year":"2023","journal-title":"Exp Hematol Oncol"}],"container-title":["International Journal of Molecular Medicine"],"original-title":[],"deposited":{"date-parts":[[2024,12,27]],"date-time":"2024-12-27T08:11:17Z","timestamp":1735287077000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.spandidos-publications.com\/10.3892\/ijmm.2024.5468"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,6]]},"references-count":105,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2024,12,6]]}},"URL":"https:\/\/doi.org\/10.3892\/ijmm.2024.5468","relation":{},"ISSN":["1107-3756","1791-244X"],"issn-type":[{"value":"1107-3756","type":"print"},{"value":"1791-244X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,6]]},"article-number":"27"}}